CD40-Mediated NF-κB Activation in B Cells Is Increased in Multiple Sclerosis and Modulated by Therapeutics

Overview

Journal J Immunol

Specialty Allergy & Immunology

Date 2016 Nov 1

PMID 27798157

Citations 28

Authors

Ding Chen

Sara J Ireland

Gina Remington

Enrique Alvarez

Michael K Racke

Benjamin Greenberg

Elliot M Frohman

Nancy L Monson

Affiliations

Soon will be listed here.

Abstract

CD40 interacts with CD40L and plays an essential role in immune regulation and homeostasis. Recent research findings, however, support a pathogenic role of CD40 in a number of autoimmune diseases. We previously showed that memory B cells from relapsing-remitting multiple sclerosis (RRMS) patients exhibited enhanced proliferation with CD40 stimulation compared with healthy donors. In this study, we used a multiparameter phosflow approach to analyze the phosphorylation status of NF-κB and three major MAPKs (P38, ERK, and JNK), the essential components of signaling pathways downstream of CD40 engagement in B cells from MS patients. We found that memory and naive B cells from RRMS and secondary progressive MS patients exhibited a significantly elevated level of phosphorylated NF-κB (p-P65) following CD40 stimulation compared with healthy donor controls. Combination therapy with IFN-β-1a (Avonex) and mycophenolate mofetil (Cellcept) modulated the hyperphosphorylation of P65 in B cells of RRMS patients at levels similar to healthy donor controls. Lower disease activity after the combination therapy correlated with the reduced phosphorylation of P65 following CD40 stimulation in treated patients. Additionally, glatiramer acetate treatment also significantly reduced CD40-mediated P65 phosphorylation in RRMS patients, suggesting that reducing CD40-mediated p-P65 induction may be a general mechanism by which some current therapies modulate MS disease.

Citing Articles

CX3CL1 (Fractalkine)-CX3CR1 Axis in Inflammation-Induced Angiogenesis and Tumorigenesis.

Szukiewicz D Int J Mol Sci. 2024; 25(9).

PMID: 38731899 PMC: 11083509. DOI: 10.3390/ijms25094679.

Semaphorin 7A impairs barrier function in cultured human corneal epithelial cells in a manner dependent on nuclear factor-kappa B.

Yang C, Yang X, Zhao X, Wang H, Guo Z, Jin K Int J Ophthalmol. 2024; 17(3):444-453.

PMID: 38721522 PMC: 11074170. DOI: 10.18240/ijo.2024.03.05.

Role of fenofibrate in multiple sclerosis.

Abulaban A, Al-Kuraishy H, Al-Gareeb A, Elekhnawy E, Alanazi A, Alexiou A Eur J Med Res. 2024; 29(1):113.

PMID: 38336772 PMC: 10854163. DOI: 10.1186/s40001-024-01700-2.

Advances in immune checkpoint-based immunotherapies for multiple sclerosis: rationale and practice.

Daei Sorkhabi A, Komijani E, Sarkesh A, Shadbad P, Aghebati-Maleki A, Aghebati-Maleki L Cell Commun Signal. 2023; 21(1):321.

PMID: 37946301 PMC: 10634124. DOI: 10.1186/s12964-023-01289-9.

Defining the Basal and Immunomodulatory Mediator-Induced Phosphoprotein Signature in Pediatric B Cell Acute Lymphoblastic Leukemia (B-ALL) Diagnostic Samples.

Khanolkar A, Liu G, Simpson Schneider B Int J Mol Sci. 2023; 24(18).

PMID: 37762241 PMC: 10531382. DOI: 10.3390/ijms241813937.

References

Jacob A, Matiello M, Wingerchuk D, Lucchinetti C, Pittock S, Weinshenker B . Neuromyelitis optica: changing concepts. J Neuroimmunol. 2007; 187(1-2):126-38. DOI: 10.1016/j.jneuroim.2007.04.009. View

Longo N, Lugar P, Yavuz S, Zhang W, Krijger P, Russ D . Analysis of somatic hypermutation in X-linked hyper-IgM syndrome shows specific deficiencies in mutational targeting. Blood. 2008; 113(16):3706-15. PMC: 2670789. DOI: 10.1182/blood-2008-10-183632. View

Remington G, Treadaway K, Frohman T, Salter A, Stuve O, Racke M . A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing-remitting multiple sclerosis (TIME MS). Ther Adv Neurol Disord. 2010; 3(1):3-13. PMC: 3002615. DOI: 10.1177/1756285609355851. View

Blair P, Norena L, Flores-Borja F, Rawlings D, Isenberg D, Ehrenstein M . CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. Immunity. 2010; 32(1):129-40. DOI: 10.1016/j.immuni.2009.11.009. View

Fitzner B, Hecker M, Zettl U . Molecular biomarkers in cerebrospinal fluid of multiple sclerosis patients. Autoimmun Rev. 2015; 14(10):903-13. DOI: 10.1016/j.autrev.2015.06.001. View

Kroese F, Abdulahad W, Haacke E, Bos N, Vissink A, Bootsma H . B-cell hyperactivity in primary Sjögren's syndrome. Expert Rev Clin Immunol. 2014; 10(4):483-99. DOI: 10.1586/1744666X.2014.891439. View

Craxton A, Shu G, Graves J, Saklatvala J, KREBS E, Clark E . p38 MAPK is required for CD40-induced gene expression and proliferation in B lymphocytes. J Immunol. 1998; 161(7):3225-36. View

Hinz M, Scheidereit C . The IκB kinase complex in NF-κB regulation and beyond. EMBO Rep. 2013; 15(1):46-61. PMC: 4303448. DOI: 10.1002/embr.201337983. View

Bishop G, Hostager B . The CD40-CD154 interaction in B cell-T cell liaisons. Cytokine Growth Factor Rev. 2003; 14(3-4):297-309. DOI: 10.1016/s1359-6101(03)00024-8. View

10.

Bishop G, Hostager B . Signaling by CD40 and its mimics in B cell activation. Immunol Res. 2001; 24(2):97-109. DOI: 10.1385/IR:24:2:097. View

11.

Fox E . Alemtuzumab in the treatment of relapsing-remitting multiple sclerosis. Expert Rev Neurother. 2010; 10(12):1789-97. DOI: 10.1586/ern.10.135. View

12.

Zhang W, Shi Q, Xu X, Chen H, Lin W, Zhang F . Aberrant CD40-induced NF-κB activation in human lupus B lymphocytes. PLoS One. 2012; 7(8):e41644. PMC: 3428310. DOI: 10.1371/journal.pone.0041644. View

13.

Lanzi G, Ferrari S, Vihinen M, Caraffi S, Kutukculer N, Schiaffonati L . Different molecular behavior of CD40 mutants causing hyper-IgM syndrome. Blood. 2010; 116(26):5867-74. DOI: 10.1182/blood-2010-03-274241. View

14.

Walker-Caulfield M, Guo Y, Johnson R, McCarthy C, Fitz-Gibbon P, Lucchinetti C . NFκB signaling drives pro-granulocytic astroglial responses to neuromyelitis optica patient IgG. J Neuroinflammation. 2015; 12:185. PMC: 4590277. DOI: 10.1186/s12974-015-0403-8. View

15.

Field J, Shahijanian F, Schibeci S, Johnson L, Gresle M, Laverick L . The MS Risk Allele of CD40 Is Associated with Reduced Cell-Membrane Bound Expression in Antigen Presenting Cells: Implications for Gene Function. PLoS One. 2015; 10(6):e0127080. PMC: 4465929. DOI: 10.1371/journal.pone.0127080. View

16.

Oh J, OConnor P . Established disease-modifying treatments in relapsing-remitting multiple sclerosis. Curr Opin Neurol. 2015; 28(3):220-9. DOI: 10.1097/WCO.0000000000000202. View

17.

Ireland S, Guzman A, Frohman E, Monson N . B cells from relapsing remitting multiple sclerosis patients support neuro-antigen-specific Th17 responses. J Neuroimmunol. 2016; 291:46-53. DOI: 10.1016/j.jneuroim.2015.11.022. View

18.

Beecham A, Patsopoulos N, Xifara D, Davis M, Kemppinen A, Cotsapas C . Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet. 2013; 45(11):1353-60. PMC: 3832895. DOI: 10.1038/ng.2770. View

19.

Gerritse K, Laman J, Noelle R, Aruffo A, Ledbetter J, Boersma W . CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci U S A. 1996; 93(6):2499-504. PMC: 39826. DOI: 10.1073/pnas.93.6.2499. View

20.

Krumbholz M, Meinl E . B cells in MS and NMO: pathogenesis and therapy. Semin Immunopathol. 2014; 36(3):339-50. DOI: 10.1007/s00281-014-0424-x. View